(ACN Newswire) – The Lubrizol Corporation’s LifeSciences business is investing $15 million to expand its global manufacturing facilities, positioning LifeSciences to better serve the growing market for medical device contract manufacturing.
Since 2014, Lubrizol LifeSciences has solidified its presence in the life sciences market by introducing new products and making strategic acquisitions. This capital investment will expand multiple facilities and increase Lubrizol LifeSciences’ in-house engineering capacity for both silicone and thermoplastic products.
“We have significantly enhanced our capabilities through the combination of strong polymer technology, application know-how and world-class component manufacturing,” states Deb Langer, vice president and general manager, Lubrizol LifeSciences. “As healthcare companies look for total solution providers, we continue to invest in the right areas to provide valuable offerings to our customers.”
Vesta, Inc., acquired by Lubrizol in August of 2014, is a leading contract manufacturer for the global medical device industry. With the addition of Vesta, Lubrizol LifeSciences now offers disposable and implantable silicone medical components and assemblies across a wide product portfolio, as well as precision thermoplastic extruded tubing. The recent acquisition of Particle Sciences, Inc., a leading contract drug development and manufacturing organization, has positioned Lubrizol LifeSciences as one of the most comprehensive drug delivery device solution providers, offering end-to-end solutions in the healthcare market.
“When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process,” states Robert Miller, global business director, medical devices. “With a long history of polymer expertise and significant investment, Lubrizol LifeSciences is positioned to offer full-service development for next generation medical and pharmaceutical innovations.”
Source: The Lubrizol Corporation
Belgian companies account for just under a quarter (24%) of the total stock market value of all public biotech companies in Europe.
Johnson & Johnson is re-upping its commitment to addressing health inequities as the pandemic lays bare long-standing divisions.
It’s estimated that 10% to 15% of people with Parkinson’s have a genetic form of the disease and Sanofi Genzyme is backing a new study to help find those people.
105744 801529Its a shame you dont have a donate button! Id most surely donate to this outstanding internet internet site! I suppose in the meantime ill be happy with bookmarking and putting your Rss feed to my Google account. I appear forward to fresh updates and will share this weblog with my Facebook group: ) 610171